"The
Report Interferon Alpha (IFNA) - Pipeline Review, H2 2016 provides
information on pricing, market analysis, shares, forecast, and
company profiles for key industry participants. -
MarketResearchReports.biz"
Global
Markets Directs, Interferon Alpha (IFNA) - Pipeline Review, H2 2016,
provides in depth analysis on Interferon Alpha (IFNA) targeted
pipeline therapeutics.
The
report provides comprehensive information on the Interferon Alpha
(IFNA) , targeted therapeutics, complete with analysis by
indications, stage of development, mechanism of action (MoA), route
of administration (RoA) and molecule type. The report also covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
Additionally, the report provides an overview of key players involved
in Interferon Alpha (IFNA) targeted therapeutics development and
features dormant and discontinued projects.
Global
Markets Directs report features investigational drugs from across
globe covering over 20 therapy areas and nearly 3,000 indications.
The report is built using data and information sourced from Global
Markets Directs proprietary databases, company/university websites,
clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university
sites and industry-specific third party sources. Drug profiles
featured in the report undergoes periodic review following a
stringent set of processes to ensure that all the profiles are
updated with the latest set of information. Additionally, various
dynamic tracking processes ensure that the most recent developments
are captured on a real time basis.
The
report helps in identifying and tracking emerging players in the
market and their portfolios, enhances decision making capabilities
and helps to create effective counter strategies to gain competitive
advantage.
View Report @
http://www.marketresearchreports.biz/analysis/928077
Scope
-
The report provides a snapshot of the global therapeutic landscape
for Interferon Alpha (IFNA)
-
The report reviews Interferon Alpha (IFNA) targeted therapeutics
under development by companies and universities/research institutes
based on information derived from company and industry-specific
sources
-
The report covers pipeline products based on various stages of
development ranging from pre-registration till discovery and
undisclosed stages
-
The report features descriptive drug profiles for the pipeline
products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental
activities
-
The report reviews key players involved in Interferon Alpha (IFNA)
targeted therapeutics and enlists all their major and minor projects
-
The report assesses Interferon Alpha (IFNA) targeted therapeutics
based on mechanism of action (MoA), route of administration (RoA) and
molecule type
-
The report summarizes all the dormant and discontinued pipeline
projects
-
The report reviews latest news and deals related to Interferon Alpha
(IFNA) targeted therapeutics
Get
Sample Copy Of This Report @
http://www.marketresearchreports.biz/sample/sample/928077
Reasons
to buy
-
Gain strategically significant competitor information, analysis, and
insights to formulate effective R&D strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Identify and understand the targeted therapy areas and indications
for Interferon Alpha (IFNA)
-
Identify the use of drugs for target identification and drug
repurposing
-
Identify potential new clients or partners in the target demographic
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Plan mergers and acquisitions effectively by identifying key players
and its most promising pipeline therapeutics
-
Devise corrective measures for pipeline projects by understanding
Interferon Alpha (IFNA) development landscape
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report
Coverage 5
Interferon Alpha (IFNA) Overview 6
Therapeutics Development 7
Interferon Alpha (IFNA) - Products
under Development by Stage of Development 7
Interferon Alpha (IFNA) - Products
under Development by Therapy Area 8
Interferon Alpha (IFNA) - Products
under Development by Indication 9
Interferon Alpha (IFNA) - Pipeline
Products Glance 10
Late Stage Products 10
Early Stage Products 11
Interferon Alpha (IFNA) - Products
under Development by Companies 12
Interferon Alpha (IFNA) -
Therapeutics Assessment 14
Assessment by
Monotherapy/Combination Products 14
Assessment by Mechanism of Action
15
Assessment by Route of
Administration 17
Assessment by Molecule Type 19
Interferon Alpha (IFNA) -
Companies Involved in Therapeutics Development 21
Argos Therapeutics Inc 21
Neovacs SA 22
PsiOxus Therapeutics Ltd 23
ZIOPHARM Oncology Inc 24
Interferon Alpha (IFNA) - Drug
Profiles 25
AGS-009 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Biosimilar to Inhibit Interferon
Alpha for Lupus Erythematosus - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
NG-345 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
RTS-IFN Alpha - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Vaccine to Target IFN-Alpha for
Chronic Viral Infections, Dermatomyositis and Systemic Lupus
Erythematosus - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Interferon Alpha (IFNA) - Dormant
Projects 34
Interferon Alpha (IFNA) -
Discontinued Products 35
Interferon Alpha (IFNA) - Featured
News & Press Releases 36
Dec 07, 2016: Neovacs obtains FDA
"Fast Track" designation for IFNa Kinoid in Lupus (SLE) 36
Nov 23, 2016: 3P
Biopharmaceuticals signs production partnership with Neovacs 36
Nov 07, 2016: Neovacs enrolls the
first U.S. Patient in Phase IIb study of IFNa Kinoid for treatment of
Systemic Lupus Erythematosus 37
Follow us on LinkedIn:
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
us:
Mr.
Nachiket
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA:
Canada Toll Free: 866-997-4948
No comments:
Post a Comment